Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma by Mizukoshi Eishiro et al.
Phase I trial of multidrug
resistance-associated protein 3-derived
peptide in patients with hepatocellular
carcinoma
著者 Mizukoshi Eishiro, Nakagawa Hidetoshi,
Kitahara Masaaki, Yamashita Tatsuya, Arai
Kuniaki, Sunagozaka Hajime, Iida Noriho,











Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
Phase I Trial of Multidrug Resistance-associated Protein 3-derived Peptide in 
Patients with Hepatocellular Carcinoma  
 
Eishiro Mizukoshi1 (eishirom@m-kanazawa.jp), Hidetoshi Nakagawa1 
(hidetoshi.naka@gmail.com), Masaaki Kitahara1(mkitahara2007@gmail.com), Tatsuya 
Yamashita1 (ytatsuya@m-kanazawa.jp), Kuniaki Arai1 (arai@m-kanazawa.jp), Hajime 
Sunagozaka1 (suna@m-kanazawa.jp), Noriho Iida1 (niida@m-kanazawa.jp), Kazumi 
Fushimi1 (k_fushimi709@yahoo.co.jp) and Shuichi Kaneko1 (skaneko@m-kanazawa.jp) 
 
1Department of Gastroenterology, Graduate School of Medicine, Kanazawa 
University, Kanazawa, Japan 
 
 
Contact Information: Shuichi Kaneko, MD 
Department of Gastroenterology, Graduate School of 
Medicine, Kanazawa University, Kanazawa, Ishikawa 
920-8641, Japan 




Word count: 3487 words 
Number of figures and tables: 4 figures and 3 tables 
2 




Abbreviations: MRP3, multidrug resistance-associated protein 3; TAA, 
tumor-associated antigen; HLA, human leukocyte antigen; IFN, 
interferon; PBMC, peripheral blood mononuclear cell; HCV, 
hepatitis C virus; ELISPOT, enzyme-linked immunospot; Treg, 
regulatory T cell; MDSC, myeloid-derived suppressor cell; CTCAE, 
Common Terminology Criteria of Adverse Events   
 
Conflict of interest: The authors report no conflict of interest. 
 
Financial Support: This work was supported in part by research grants from the 
Ministry of Education, Culture, Sports, Science and Technology 









Multidrug resistance-associated protein 3 (MRP3) is a carrier-type transport protein 
belonging to the ABC transporters. In this study, we investigated the safety and 
immunogenicity of a MRP3-derived peptide (MRP3765) as a vaccine and characterized 
the MRP3-specific T cell responses induced. Twelve hepatocellular carcinoma (HCC) 
patients treated with hepatic arterial infusion chemotherapy (HAIC) were enrolled. The 
MRP3-derived peptide was emulsified in incomplete Freund’s adjuvant and administered 
via subcutaneous immunization three times weekly. No serious adverse drug reactions to 
the peptide vaccine were observed, and the vaccination was well tolerated. The 
vaccination induced MRP3-specific immunity in 72.7% of the patients. In a phenotypic 
analysis, the largest post-vaccinated increase in MRP3-specific T cells was due to an 
increase in cells with the effector memory phenotype. Among the 12 patients, one patient 
showed a partial response, nine showed a stable disease, and two showed a progressive 
disease. The median overall survival time was 14.0 months. In conclusion, the safety, 
effects of immune boosting, and possible prolongation of overall survival by the 
MRP3-derived peptide demonstrate the potential of the peptide to provide clinical benefit 
in HCC patients. 
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Hepatocellular carcinoma (HCC), the sixth most frequent type of cancer worldwide, is 
an important public health concern because its incidence has continued to increase in 
Western and Asian countries [1; 2]. Advanced HCC is treated with sorafenib as the 
standard treatment. This is the sole systemic agent available and can prolong survival for 
2.3–2.8 months [3; 4]. Hepatic arterial infusion chemotherapy (HAIC) has been used as 
an alternative therapy to sorafenib in Japan and other Asian countries [5; 6]. However, 
when no curative treatment is administered at the time of the diagnosis of advanced HCC, 
the median survival of patients is currently less than 1 year [7]. Thus, there is a continuing 
need for novel treatment strategies to improve the outcomes of advanced HCC patients. 
Some recently developed immunotherapies have turned out to be promising strategies for 
several advanced cancers. As with other cancers, immunotherapy is expected to provide 
new treatments for HCC. 
Multidrug resistance-associated protein 3 (MRP3) is a carrier-type transport protein 
belonging to the ABC transporters that transport substances against a concentration 
gradient in an ATP energy-dependent manner [8]. It is expressed at high levels in the 
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small and large intestines, pancreas, placenta, and adrenal cortex [9], and recent studies 
have reported that its expression is enhanced in various cancer cells [10; 11; 12].  
We previously demonstrated that the MRP3 expression level in HCC tissue was 
significantly higher than in non-cancerous tissue and that MRP3-specific cytotoxic T 
cells (CTLs), which showed cytotoxicity against HCC cells overexpressing MRP3, could 
be induced regardless of liver function, blood α-fetoprotein (AFP) level, and the stage of 
HCC [13]. These results suggest that MRP3 may be useful as a target antigen in HCC 
immunotherapy. 
Clinical trials using MRP3-derived peptides have been performed in cancer patients, 
and the results have shown that the peptide vaccine is well tolerated and effective for 
patients with glioblastoma and prostate cancer [14; 15]. However, the safety and efficacy 
of MRP3-derived peptide vaccines in HCC patients remain unclear. 
The results of recent studies have also suggested that combination therapies of a 
peptide vaccine and conventional chemotherapy can enhance the anti-tumor effects of 
peptides [16; 17]. In this study, the safety and immunological effects of a MRP3-derived 
peptide used as a potential vaccine in HCC patients treated with HAIC were investigated. 
Furthermore, we characterized the phenotype of MRP3-specific T cells induced by the 
peptide and monitored the MRP3-specific immune response, the numbers of regulatory T 
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cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and the anti-tumor effects 
on HCC after vaccination.  
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2. MATERIALS AND METHODS  
 
2.1 Patients  
Twelve HLA-A24-positive HCC patients were enrolled (Table 1). The inclusion 
criteria were a histological or radiological diagnosis of primary HCC according to the 
American Association for the Study of Liver Diseases (AASLD) guidelines for the 
management of HCC [18], a Karnofsky score of ≥70%, ≥20 years of age, informed 
consent, and the following normal baseline hematological parameters: hemoglobin 
≥8.5 g/dL, white blood cell count ≥2,000/µL, platelet count ≥50,000/µL, creatinine 
≤1.5 mg/dL, and Child–Pugh class A or B. Regarding tumor stage, the following patients 
were included: patients who had (1) severe vascular invasion (i.e., vascular invasion in 
the main trunk to the secondary branches of the portal vein or invasion in the right, middle, 
or left hepatic vein) and (2) multiple intrahepatic lesions (i.e., five or more nodules in the 
left and/or right lobes, as confirmed by radiology). 
Exclusion criteria included severe cardiac, renal, pulmonary, hematological, or other 
systemic diseases associated with a discontinuation risk. Such diseases included human 
immunodeficiency virus (HIV) infection; prior history of other malignancies; history of 
surgery, chemotherapy, or radiation therapy within 4 weeks of the trial; immunological 
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disorders, including splenectomy and radiation to the spleen; corticosteroid or 
anti-histamine therapy; currently lactating or pregnant; history of organ transplantation; 
or difficulty in follow up. 
 
2.2 Treatment protocol 
The present study was designed as a phase I trial. Primary endpoints were the 
evaluation of the safety and immunological effects of the MRP3765 peptide vaccine. The 
secondary endpoint was the anti-tumor response. After starting treatment, HCC 
progression was evaluated with dynamic CT or MRI every 2–3 months. 
After diagnosis, all patients were treated with HAIC using pegylated (PEG) interferon 
(IFN)-α-2b/5-fluorouracil (FU) + cisplatin at Kanazawa University Hospital between 
April 2011 and December 2012. The patients received a continuous hepatic arterial 
infusion of FU (5-FU, Kyowa Hakko, Tokyo, Japan) at a dose of 300 mg/m2/day for 5 
days in the first and second weeks (for 120 h) using an infusion pump (Baxter Infusor 
SV1, Tokyo, Japan), as described previously [19]. The maximum amount of FU infused 
over 5 days was 2,500 mg. PEG IFN α-2b (Schering-Plough, Osaka, Japan) at a dose of 
1.0 µg/kg was administered s.c. on days 1, 8, 15, and 22. A dose of 20 mg/m2 Cisplatin 
(Nippon Kayaku, Tokyo, Japan) was given by a hepatic arterial infusion over 1.5 h on 
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days 1 and 8 prior to the administration of FU and after appropriate hydration and 
antiemetic medication. A treatment cycle comprised 4 weeks of drug administration, 
including the administration of IFN, and a subsequent 2-week rest period. 
Patients also received 0.03–3.0 mg MRP3-derived peptide (MRP3765) vaccine on days 
1, 8, and 15 during HAIC. The peptide was administered emulsified with incomplete 
Freund’s adjuvant (Montanide ISA-51 VG; SEPPIC, Paris, France) by subcutaneous 
immunization. Vaccination was also performed during the second course of HAIC. 
Adverse events/toxicities were categorized and graded using the Common Terminology 
Criteria of Adverse Events (CTCAE; ver. 3.0). Criteria for discontinuation included 
unacceptable toxicity and disease progression, defined as progressive disease (PD) 
according to the RECIST criteria. 
All patients provided written informed consent for their participation in the study in 
accordance with the Helsinki declaration. This study (trial registration: 
UMIN000005678) was approved by the regional ethics committee (Medical Ethics 
Committee, Kanazawa University, No. 1018). 
 
2.3 Peptides and preparation of PBMCs 
The HCC patients were immunized with the MRP3765 peptide, which was synthesized 
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to GMP grade (Neo MPS, Inc., San Diego, CA, USA). For the immunological analysis, 
the peptide derived from MRP3 (Peptide 1, MRP3765), the HIV envelope-derived peptide 
(Peptide 2, HIVenv584) [20], and the CMV pp65-derived peptide (Peptide 3, 
CMVpp65328) [21] were used (Sumitomo Pharmaceuticals, Osaka, Japan). PBMCs were 
isolated prior to and 2 weeks after final vaccination in every course, as described 
previously [22]. In some available patients, PBMCs were also isolated 24 weeks after 
starting HAIC. PBMCs were resuspended in RPMI 1640 medium containing 80% fetal 
calf serum (FCS) and 10% dimethyl sulfoxide and then cryopreserved until use. 
 
2.4 IFN-γ ELISPOT assay 
IFN-γ ELISPOT assays were performed, as reported previously [23]. The number of 
spots in control wells was fewer than 10 in all ELISPOT assays. Responses to the 
MRP3-derived peptides were considered positive if more than the mean + 2 SD specific 
spots were detected in healthy normal donors and the number of spots detected in the 
presence of an antigen was at least two-fold that detected in its absence. 
 
2.5 Flow cytometric analysis 
Peptide MRP3765-specific tetramer was used for the detection of peptide 
12 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
vaccine-induced CTLs. Peptide HIVenv584-specific tetramer was used as a negative 
control of tetramer assay. All tetramers were purchased from Medical Biological 
Laboratories Co., Ltd. (Nagoya, Japan). PBMCs were stained with anti-CD8-APC 
(Becton Dickinson, Tokyo, Japan), anti-CCR7-FITC (eBioscience, Tokyo, Japan), 
anti-CD45RA-PerCP-Cy5.5 antibodies (eBioscience, Tokyo, Japan), and with 
tetramer-PE for 30 min at room temperature. Cells were washed, fixed with 0.5% 
paraformaldehyde/PBS, and analyzed using a Becton Dickinson FACSAria II system. In 
the tetramer assays with the negative control tetramer, we did not observe more than 
0.03% tetramer-positive cells in any assay. Based on the results of the negative control, 
responses to MRP765-specific tetramer were considered positive if more than 0.03% 
tetramer positive cells were detected. At least 1,000,000 PBMCs were acquired for each 
tetramer assay. For the detection of Tregs and MDSCs, the following anti-human 
monoclonal antibodies were used: anti-CD4 (Becton Dickinson), anti-CD14 (Becton 
Dickinson), anti-CD25 (Becton Dickinson), anti-CD127 (Becton Dickinson), and 
anti-HLA-DR (Becton Dickinson). 
 
2.6 Statistical analysis 
Data are expressed as means ± SD. Paired t-tests were used for statistical analyses of 
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the frequency of MRP3765 peptide-specific T cells, Tregs, and MDSCs before and after 
HAIC with the MRP3765 peptide vaccine. We used the Kaplan–Meier method to estimate 
the distribution of progression-free survival (PFS) and overall survival (OS) rates. PFS 
was calculated from the first day of HAIC to the date of radiographic disease progression 
using the RECIST criteria. OS was calculated from the first day of HAIC to the date of 
death from any cause. A per-protocol statistical analysis was performed using the SPSS 









3.1 Patient profiles 
Clinical profiles of the patients are shown in Table 1. All patients but one (patient C2) 
received 3–6 vaccinations and were evaluated with immunological analyses. The 
etiology of liver diseases consisted of HCV, HBV, and other for 7, 0, and 5 patients, 
respectively. Ten patients had liver cirrhosis, proven by liver biopsy. The TNM stage was 
classified according to the Liver Cancer Study Group of Japan (LCSGJ): 4, 3, and 5 
patients had stages II, III, and IV, respectively. 
 
3.2 Toxicity of the MRP3-derived peptide vaccine 
Adverse events/toxicities were categorized and graded using the CTCAE. As shown in 
Table 2, three (25.0%) patients showed grade 1 fever. One (8.3%), three (25.0%), two 
(16.7%), and one (8.3%) patient developed dizziness, ascites, gastric ulcer, and arthralgia, 
respectively. Blood examinations revealed reductions in neutrophil or platelet counts in 
each patient. These adverse events were considered to be related to HAIC, as reported 
previously [5; 24]. No severe adverse event related to the MRP3765 peptide vaccine was 
observed. 
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3.3 CTL response 
CTL responses before and 2 weeks after final vaccination were evaluated using an 
IFN-γ ELISPOT assay. Comparisons of the frequency of each peptide-specific CTL 
before and 2 weeks after vaccination in all patients except one (patient C2) are shown in 
Figure 1A. The frequencies of MRP3765 peptide (peptide 1)-specific CTLs before 
vaccination were 0-2 per 3×105 PBMCs. The frequencies of HIVenv584 (peptide 2)- and 
CMVpp65328 peptide (peptide 3)-specific CTLs before vaccination were 0-2.5 and 1-230 
per 3×105 PBMCs, respectively. 
When T cell responses against a single peptide with >2.9 specific spots (i.e., > mean + 
2 SDs of the frequency of MRP3765-specific T cells in healthy controls) and a two-fold 
increase were defined as significant, a significant increase in the MRP3765 peptide was 
observed in 8 of 11 (72.7%) patients (patients A1, A3, B3, C1, C3, C4, C5, and C6). In 
contrast, no increase in the frequency of HIVenv584 peptide-specific CTLs was observed 
in any patient. The frequency of CMVpp65328 peptide-specific CTLs increased in 3 of 11 
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3.4 Phenotypic analysis of CTLs induced by vaccination 
The frequency of MRP3765 peptide-specific CTLs was also examined using tetramer 
analysis, and the memory phenotype of tetramer-positive cells was analyzed using 
CD45RA/CCR7 expression criteria [25]. In one patient (patient C6), MRP3765 tetramer
+ 
CD8+ T cells were readily detectable after vaccination without in vitro stimulation with 
the peptide. Figure 1B presents representative results for patient C6 with respect to 
changes in the frequency of MRP3765 peptide-specific CTLs evaluated by tetramer 
analysis before and 2 weeks after vaccination. The frequencies of MRP3765 
peptide-specific CTLs were 0.01% and 0.19% of CD8+ T cells pre- and post-vaccination, 
respectively. According to phenotypic analysis of MRP3765 peptide-specific CD8
+ T cells 
after vaccination, the frequencies of CD45RA-/CCR7+ (central memory), 
CD45RA-/CCR7- (effector memory), and CD45RA+/CCR7- (effector) T cells were 0.4%, 
74.4%, and 24.8% of the MRP3765 tetramer
+ CD8+ T cells, respectively. In contrast, 
phenotypic analysis of total CD8+ T cells after vaccination showed that the frequencies of 
CD45RA-/CCR7+ (central memory), CD45RA-/CCR7- (effector memory), and 
CD45RA+/CCR7- (effector) T cells were 10.7%, 39.4%, and 38.6% of CD8+ T cells, 
respectively (Fig. 1C). 
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3.5 Detection of Tregs and MDSCs 
In addition to the analysis of MRP3765 peptide-specific CD8
+ T cells, we examined the 
frequency of Tregs and MDSCs in peripheral blood to identify the effects of HAIC with 
the peptide vaccine on immune suppressor cells. The population of Tregs was detected as 
CD4+ CD25+ CD127-/low cells, as reported previously (Fig. 2A) [26]. The population of 
MDSCs was detected as CD14+HLA-DR-/low cells, as reported previously (Fig. 2B) [26]. 
The frequencies of MRP3765 peptide-specific CD8
+ T cells (Fig. 2C), Tregs (Fig. 2D) and 
of MDSCs (Fig. 2E) in peripheral blood before and after HAIC with peptide vaccine are 
shown for each patient.  
The frequency of MRP3765 peptide-specific CD8
+ T cells detected in the IFN-γ 
ELISPOT assay increased significantly after the treatment (p = 0.007; Fig. 2C). The 
frequency of Tregs varied greatly (4.5–12.9%) in the HCC patients before treatment and 
decreased significantly after treatment (p = 0.040; Fig. 2D). The frequency of MDSCs in 
the PBMCs of HCC patients represented 8.0–32.6% of CD14+ cells before HAIC. In 
contrast to Tregs, this increased significantly after treatment (p = 0.022; Fig. 2E). 
 
3.6 Kinetics of peptide-specific CTLs after vaccination 
To evaluate the kinetics of MRP3765 peptide-specific CTLs after vaccination, the 
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frequency of CTLs 24 weeks after vaccination was examined in six patients (A3, B3, C1, 
C4, C5, and C6) whose PBMCs were available for ELISPOT assays. The frequency of 
MRP3765 peptide-specific CTLs, evaluated using an IFN-γ ELISPOT assay 24 weeks 
after vaccination was 0–3 cells per 3×105 PBMCs, and no patient maintained a level of 
>10 cells per 3×105 PBMCs (Fig. 3A). With the exception of three patients (patients A3, 
B3, and C6), the frequencies of CMV- and HIV-derived peptide-specific CTLs did not 
decrease during the study course,  
 
3.7 Clinical outcomes 
A summary of the immune and tumor responses in all patients after vaccination with 
the MRP3765 peptide is shown in Table 3. According to the RECIST criteria, among the 
12 patients, one patient showed a partial response (PR), nine showed a stable disease 
(SD), and two showed a progressive disease (PD). The overall survival time for each 
patient is presented in Table 3. At the time of writing, all patients have shown disease 
progression with death, and the median overall survival time was 14.0 months (95% CI = 
9.6–18.5 months)(Fig. 3B), which is longer than those in previous studies including 
patients treated with HAIC without peptide vaccination (median OS = 12.0–12.6 months) 
[24; 27]. 
19 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
The representative clinical course of the patient with PR is shown in Figure 4. The 
patient with PR (Patient B3) had a large HCC in the right lobe of the liver and was 
vaccinated with the MRP3765 peptide weekly, for a total of six times. After vaccination, 
elevated serum AFP and DCP values normalized within 100 days (Fig. 4A), and the size 
of the HCC (Fig. 4B), evaluated by CT, was getting smaller. During the vaccination, ALT 
was elevated to the abnormal limit, but it normalized after the final vaccination (Fig. 4A). 
The frequencies of MRP3765 peptide-specific CTLs before and after vaccination are 
shown in Figure 4C. The frequency of MRP3765 peptide-specific CTLs increased after 
vaccination. However, the frequencies of HIVenv peptide-specific CTLs were unchanged 
during vaccination, and those of CMVpp65 peptide-specific CTLs fluctuated. 
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In previous studies, we performed a simultaneous and comparative analysis of immune 
responses to 27 different CTL epitopes derived from 14 TAAs using PBMCs from HCC 
patients to identify suitable TAA-derived epitopes for HCC immunotherapy [28]. We 
found that MRP3-derived peptides were frequently recognized by T cells and were 
capable of generating peptide-specific CTLs in HCC patients, suggesting that these 
peptides were immunogenic.  
In this phase I study, immunotherapy using the MRP3765 peptide in a formulation with 
the Montanide ISA-51 adjuvant was shown to be safe and immunogenic. The maximum 
toxicity observed was grade 3, according to the common terminology criteria, and it was 
actually considered to be due to the HAIC. Adverse events observed frequently were 
fever, ascites, and gastric ulcer, and these are also known common adverse events of 
HAIC [5; 24]. IFN-γ ELISPOT assays revealed that vaccination with the MRP3765 
peptide induced MRP3-specific immunity in 8 of 11 (72.7%) vaccinated patients. In 
previous studies of peptide vaccines for HCC, AFP, hTERT, and glypican-3 have been 
targeted as tumor-associated antigens for the treatment of advanced HCC [29; 30; 31; 32; 
33]. In these studies, peptide-specific T cells were reported to be induced in 0–80% of the 
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patients vaccinated. Thus, the induction rate of TAA-derived peptide-specific T cell 
responses in MRP3765 peptide vaccination was similar to those of AFP- or 
glypican-3-derived peptides, suggesting that the MRP3765 peptide was immunogenic. 
In phenotypic analyses of CTLs induced by the MRP3765 peptide vaccine, the 
post-vaccination increase in MRP3765 peptide-specific CTLs was due to increases in cells 
with the CD45RA-/CCR7- (effector memory) and CD45RA+/CCR7- (effector) 
phenotypes. A similar phenotypic analysis was reported by Butterfield et al. [34], who 
identified AFP-specific CTLs induced by AFP-derived peptide-pulsed DCs that were 
both naïve and of the central memory phenotype and failed to complete differentiation 
into effector and effector memory T cells. Differences between the present study and the 
previous one involved the administration method of the peptide vaccine and the use of 
combined therapy. In the previous study, they used dendritic cells pulsed with multiple 
peptides and with no additional treatment. All the patients in this study simultaneously 
received HAIC with the peptide vaccination. Recent studies reported that anti-tumor 
chemotherapy produced its anti-tumor effects by not only direct cytotoxic effects against 
tumor cells but also by the elimination or inactivation of cells with suppressive effects on 
tumor immunity, such as Tregs and MDSCs [35; 36]. In fact, the frequency of Tregs 
decreased after the treatment, which was consistent with the previously reported 
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responses of Tregs to chemotherapy against colon cancer using cyclophosphamide and 
against non-small cell lung cancer using paclitaxel [37; 38]. This may indicate more 
favorable conditions for the induction of peptide-specific T cells with effector memory or 
effector phenotypes. 
Although peptide-specific CTLs and the effector memory phenotype could be induced 
in this study, the anti-tumor effects for HCC were limited, which is consistent with 
previous studies of peptide vaccines for HCC [31; 33]. One reason might be the slow 
speed and weakness of the anti-tumor effects induced by the peptide vaccine. In this study, 
the induction rate of MRP3765 peptide-specific T cells and their frequencies during the 
first course of vaccination were low. Another reason may be the short life of MRP3765 
peptide-specific T cells. The frequency of MRP3765 peptide-specific T cells decreased 
after 6 months in most patients, suggesting 3–6 injections of the MRP3765 peptide was not 
sufficient to induce long-lived T cells. Furthermore, the advanced HCC stages of the 
patients or continued HAIC may affect the short life of MRP3765 peptide-specific T cells. 
The frequency of MDSCs increased significantly after the treatment in some of the 
patients. This phenomenon is considered to be unfavorable to anti-tumor immunity. In 
fact, among the 8 patients who showed MRP3765 peptide-specific CTLs in PBMCs after 1 
or 2 course vaccination, 5 patients (patients B3, C1, C3, C4 and C5) did not show a 
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significant increase (more than 10%) of MDSCs (Table 3). In addition, all of the patients 
without a significant increase of MDSCs after vaccination showed PR or SD as a best 
study response. Although it is difficult to clearly state the relationship between the 
increase of MDSCs and the anti-tumor effect of vaccination because of small number of 
patients in this study, these results suggest that the small number of MDSCs in PBMCs 
might be favorable conditions for the induction of peptide-specific CTLs and contribute 
to the anti-tumor effect of peptide vaccination. 
Regarding the effects of MRP3765 peptide on the prognosis of HCC patients, obviously 
this is limited because our study was designed as a phase I study and did not involve a 
large population. However, the results of the present study suggest that the overall 
survival times of the patients treated with HAIC with the peptide vaccine was longer than 
those in previous studies including patients treated with HAIC with no peptide 
vaccination. To confirm these results, larger, later-stage clinical trials are necessary. 
Specifically, HAIC with more than 6 times injection of MRP3-derived peptide or the 
combination with the inhibitors of MDSCs such as low dose gemcitabine, cisplatin or 
5-FU should be tried as a next clinical trial. Furthermore, previous studies have 
demonstrated that Sorafenib decreases the number of MDSCs [39; 40], and therefore the 
vaccination of MRP3-derived peptide with Sorafenib might be effective for patients with 
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HCC. 
In conclusion, the feasibility of a MRP3-derived peptide vaccine has been 
demonstrated based on its safety, its effect on immune boosting, and even the possible 
prolongation of overall survival time. The potential to eradicate advanced HCC using a 
combination therapy of a peptide vaccine and chemotherapy should be further evaluated 
in additional studies.  
 
25 





This study was supported by research grants from the Ministry of Education, Culture, 
Sports, Science, and Technology of Japan (22590723 and 25460984). 
26 




[1]J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127 (2010) 
2893-2917. 
[2]J.A. Davila, R.O. Morgan, Y. Shaib, K.A. McGlynn, H.B. El-Serag, Hepatitis C 
infection and the increasing incidence of hepatocellular carcinoma: a 
population-based study. Gastroenterology 127 (2004) 1372-1380. 
[3]J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, 
A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, 
T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. 
Shan, M. Moscovici, D. Voliotis, J. Bruix, Sorafenib in advanced hepatocellular 
carcinoma. N Engl J Med 359 (2008) 378-390. 
[4]S. Kaneko, J. Furuse, M. Kudo, K. Ikeda, M. Honda, Y. Nakamoto, M. Onchi, G. 
Shiota, O. Yokosuka, I. Sakaida, T. Takehara, Y. Ueno, K. Hiroishi, S. Nishiguchi, 
H. Moriwaki, K. Yamamoto, M. Sata, S. Obi, S. Miyayama, Y. Imai, Guideline 
on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 
2010 update. Hepatol Res 42 (2012) 523-542. 
27 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
[5]T. Terashima, T. Yamashita, K. Arai, H. Sunagozaka, M. Kitahara, H. Nakagawa, T. 
Kagaya, E. Mizukoshi, M. Honda, S. Kaneko, Feasibility and efficacy of hepatic 
arterial infusion chemotherapy for advanced hepatocellular carcinoma after 
sorafenib. Hepatol Res 44 (2014) 1179-1185. 
[6]S. Song do, M.J. Song, S.H. Bae, W.J. Chung, J.Y. Jang, Y.S. Kim, S.H. Lee, J.Y. Park, 
H.J. Yim, S.B. Cho, S.Y. Park, J.M. Yang, A comparative study between 
sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular 
carcinoma with portal vein tumor thrombosis. J Gastroenterol 50 (2015) 445-454. 
[7]M. Pinter, F. Hucke, I. Graziadei, W. Vogel, A. Maieron, R. Konigsberg, R. Stauber, B. 
Grunberger, C. Muller, C. Kolblinger, M. Peck-Radosavljevic, W. Sieghart, 
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization 
versus sorafenib. Radiology 263 (2012) 590-599. 
[8]P. Borst, R.O. Elferink, Mammalian ABC transporters in health and disease. Annu 
Rev Biochem 71 (2002) 537-592. 
[9]Y. Kiuchi, H. Suzuki, T. Hirohashi, C.A. Tyson, Y. Sugiyama, cDNA cloning and 
inducible expression of human multidrug resistance associated protein 3 (MRP3). 
FEBS Lett 433 (1998) 149-152. 
[10]A. Yamada, K. Kawano, M. Koga, T. Matsumoto, K. Itoh, Multidrug 
28 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
resistance-associated protein 3 is a tumor rejection antigen recognized by 
HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 61 (2001) 
6459-6466. 
[11]Y. Tada, M. Wada, T. Migita, J. Nagayama, E. Hinoshita, Y. Mochida, Y. Maehara, 
M. Tsuneyoshi, M. Kuwano, S. Naito, Increased expression of multidrug 
resistance-associated proteins in bladder cancer during clinical course and drug 
resistance to doxorubicin. Int J Cancer 98 (2002) 630-635. 
[12]L.C. Young, B.G. Campling, S.P. Cole, R.G. Deeley, J.H. Gerlach, Multidrug 
resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of 
protein levels with drug response and messenger RNA levels. Clin Cancer Res 7 
(2001) 1798-1804. 
[13]E. Mizukoshi, M. Honda, K. Arai, T. Yamashita, Y. Nakamoto, S. Kaneko, 
Expression of multidrug resistance-associated protein 3 and cytotoxic T cell 
responses in patients with hepatocellular carcinoma. J Hepatol 49 (2008) 
946-954. 
[14]M. Terasaki, S. Shibui, Y. Narita, T. Fujimaki, T. Aoki, K. Kajiwara, Y. Sawamura, 
K. Kurisu, T. Mineta, A. Yamada, K. Itoh, Phase I trial of a personalized peptide 
vaccine for patients positive for human leukocyte antigen--A24 with recurrent or 
29 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
progressive glioblastoma multiforme. J Clin Oncol 29 (2011) 337-344. 
[15]M. Noguchi, F. Moriya, S. Suekane, R. Ohnishi, S. Matsueda, T. Sasada, A. Yamada, 
K. Itoh, A phase II trial of personalized peptide vaccination in castration-resistant 
prostate cancer patients: prolongation of prostate-specific antigen doubling time. 
BMC Cancer 13 (2013) 613. 
[16]C.N. Baxevanis, S.A. Perez, M. Papamichail, Combinatorial treatments including 
vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer 
Immunol Immunother 58 (2009) 317-324. 
[17]R. Ramakrishnan, D. Assudani, S. Nagaraj, T. Hunter, H.I. Cho, S. Antonia, S. Altiok, 
E. Celis, D.I. Gabrilovich, Chemotherapy enhances tumor cell susceptibility to 
CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120 
(2010) 1111-1124. 
[18]J. Bruix, M. Sherman, Management of hepatocellular carcinoma: an update. 
Hepatology 53 (2011) 1020-1022. 
[19]H. Ota, H. Nagano, M. Sakon, H. Eguchi, M. Kondo, T. Yamamoto, M. Nakamura, B. 
Damdinsuren, H. Wada, S. Marubashi, A. Miyamoto, K. Dono, K. Umeshita, S. 
Nakamori, K. Wakasa, M. Monden, Treatment of hepatocellular carcinoma with 
major portal vein thrombosis by combined therapy with subcutaneous 
30 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor 
expression. Br J Cancer 93 (2005) 557-564. 
[20]Y. Ikeda-Moore, H. Tomiyama, K. Miwa, S. Oka, A. Iwamoto, Y. Kaneko, M. 
Takiguchi, Identification and characterization of multiple HLA-A24-restricted 
HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J 
Immunol 159 (1997) 6242-6252. 
[21]K. Kuzushima, N. Hayashi, H. Kimura, T. Tsurumi, Efficient identification of 
HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a 
computer algorithm and an enzyme-linked immunospot assay. Blood 98 (2001) 
1872-1881. 
[22]E. Mizukoshi, Y. Nakamoto, H. Tsuji, T. Yamashita, S. Kaneko, Identification of 
alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in 
HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 118 (2006) 
1194-1204. 
[23]E. Mizukoshi, Y. Nakamoto, Y. Marukawa, K. Arai, T. Yamashita, H. Tsuji, K. 
Kuzushima, M. Takiguchi, S. Kaneko, Cytotoxic T cell responses to human 
telomerase reverse transcriptase in patients with hepatocellular carcinoma. 
Hepatology 43 (2006) 1284-1294. 
31 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
[24]T. Yamashita, K. Arai, H. Sunagozaka, T. Ueda, T. Terashima, E. Mizukoshi, A. 
Sakai, Y. Nakamoto, M. Honda, S. Kaneko, Randomized, phase II study 
comparing interferon combined with hepatic arterial infusion of fluorouracil plus 
cisplatin and fluorouracil alone in patients with advanced hepatocellular 
carcinoma. Oncology 81 (2011) 281-290. 
[25]F. Sallusto, D. Lenig, R. Forster, M. Lipp, A. Lanzavecchia, Two subsets of memory 
T lymphocytes with distinct homing potentials and effector functions. Nature 401 
(1999) 708-712. 
[26]F. Arihara, E. Mizukoshi, M. Kitahara, Y. Takata, K. Arai, T. Yamashita, Y. 
Nakamoto, S. Kaneko, Increase in CD14+HLA-DR -/low myeloid-derived 
suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. 
Cancer Immunol Immunother 62 (2013) 1421-1430. 
[27]T. Terashima, T. Yamashita, N. Iida, H. Nakagawa, K. Arai, K. Kitamura, T. Kagaya, 
Y. Sakai, E. Mizukoshi, M. Honda, S. Kaneko, Blood neutrophil to lymphocyte 
ratio as a predictor in patients with advanced hepatocellular carcinoma treated 
with hepatic arterial infusion chemotherapy. Hepatol Res (2014). 
[28]E. Mizukoshi, Y. Nakamoto, K. Arai, T. Yamashita, A. Sakai, Y. Sakai, T. Kagaya, 
M. Honda, S. Kaneko, Comparative analysis of various tumor-associated 
32 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
antigen-specific t-cell responses in patients with hepatocellular carcinoma. 
Hepatology 53 (2011) 1206-1216. 
[29]P.F. Brunsvig, S. Aamdal, M.K. Gjertsen, G. Kvalheim, C.J. Markowski-Grimsrud, I. 
Sve, M. Dyrhaug, S. Trachsel, M. Moller, J.A. Eriksen, G. Gaudernack, 
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell 
lung cancer. Cancer Immunol Immunother 55 (2006) 1553-1564. 
[30]T.F. Greten, A. Forner, F. Korangy, G. N'Kontchou, N. Barget, C. Ayuso, L.A. 
Ormandy, M.P. Manns, M. Beaugrand, J. Bruix, A phase II open label trial 
evaluating safety and efficacy of a telomerase peptide vaccination in patients with 
advanced hepatocellular carcinoma. BMC Cancer 10 (2010) 209. 
[31]L.H. Butterfield, A. Ribas, V.B. Dissette, Y. Lee, J.Q. Yang, P. De la Rocha, S.D. 
Duran, J. Hernandez, E. Seja, D.M. Potter, W.H. McBride, R. Finn, J.A. Glaspy, 
J.S. Economou, A phase I/II trial testing immunization of hepatocellular 
carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein 
peptides. Clin Cancer Res 12 (2006) 2817-2825. 
[32]T. Yoshikawa, M. Nakatsugawa, S. Suzuki, H. Shirakawa, D. Nobuoka, N. Sakemura, 
Y. Motomura, Y. Tanaka, S. Hayashi, T. Nakatsura, HLA-A2-restricted 
glypican-3 peptide-specific CTL clones induced by peptide vaccine show high 
33 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
avidity and antigen-specific killing activity against tumor cells. Cancer Sci 102 
(2011) 918-925. 
[33]Y. Sawada, T. Yoshikawa, D. Nobuoka, H. Shirakawa, T. Kuronuma, Y. Motomura, 
S. Mizuno, H. Ishii, K. Nakachi, M. Konishi, T. Nakagohri, S. Takahashi, N. 
Gotohda, T. Takayama, K. Yamao, K. Uesaka, J. Furuse, T. Kinoshita, T. 
Nakatsura, Phase I trial of a glypican-3-derived peptide vaccine for advanced 
hepatocellular carcinoma: immunologic evidence and potential for improving 
overall survival. Clin Cancer Res 18 (2012) 3686-3696. 
[34]L.H. Butterfield, A. Ribas, D.M. Potter, J.S. Economou, Spontaneous and vaccine 
induced AFP-specific T cell phenotypes in subjects with AFP-positive 
hepatocellular cancer. Cancer Immunol Immunother 56 (2007) 1931-1943. 
[35]D. Alizadeh, N. Larmonier, Chemotherapeutic targeting of cancer-induced 
immunosuppressive cells. Cancer Res 74 (2014) 2663-2668. 
[36]Y. Zheng, Y. Dou, L. Duan, C. Cong, A. Gao, Q. Lai, Y. Sun, Using chemo-drugs or 
irradiation to break immune tolerance and facilitate immunotherapy in solid 
cancer. Cell Immunol 294 (2015) 54-59. 
[37]F. Ghiringhelli, N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. 
Chauffert, E. Solary, B. Bonnotte, F. Martin, CD4+CD25+ regulatory T cells 
34 
Mizukoshi et al.   Phase I Trial of MRP3-Derived peptide for HCC. 
 
suppress tumor immunity but are sensitive to cyclophosphamide which allows 
immunotherapy of established tumors to be curative. Eur J Immunol 34 (2004) 
336-344. 
[38]L. Zhang, K. Dermawan, M. Jin, R. Liu, H. Zheng, L. Xu, Y. Zhang, Y. Cai, Y. Chu, 
S. Xiong, Differential impairment of regulatory T cells rather than effector T cells 
by paclitaxel-based chemotherapy. Clin Immunol 129 (2008) 219-229. 
[39]M. Cao, Y. Xu, J.I. Youn, R. Cabrera, X. Zhang, D. Gabrilovich, D.R. Nelson, C. Liu, 
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a 
murine liver cancer model. Lab Invest 91 (2011) 598-608. 
[40]T. Kapanadze, J. Gamrekelashvili, C. Ma, C. Chan, F. Zhao, S. Hewitt, L. Zender, V. 
Kapoor, D.W. Felsher, M.P. Manns, F. Korangy, T.F. Greten, Regulation of 
accumulation and function of myeloid derived suppressor cells in different 










Figure 1. Immune responses of PBMCs to MRP3-derived peptide (Peptide 1, MRP3765) 
or control peptides (Peptide 2, HIVenv584 and Peptide 3, CMVpp65328) in vaccinated 
HCC patients. (A) IFN-γ ELISPOT assays using PBMCs from vaccinated HCC patients 
and MRP3-derived or control peptides. White and black bars show the T cell responses 
before and after vaccination, respectively. * denotes more than 30 specific spots. (B) 
Peptide MRP3765-specific tetramer was used for the detection of peptide vaccine-induced 
CTLs. The Representative results are shown (patient C6). The frequencies of MRP3765 
peptide-specific CTLs were 0.01% and 0.19% of CD8+ T cells pre- and post-vaccination, 
respectively. (C) Phenotypic analysis of CTLs induced by vaccine. The memory 
phenotype of tetramer-positive cells was analyzed using CD45RA/CCR7 expression 
criteria. Phenotypic analysis of MRP3765 peptide-specific CD8
+ T cells after vaccination 
showed that the frequencies of CD45RA-/CCR7+ (central memory), CD45RA-/CCR7- 
(effector memory), and CD45RA+/CCR7- (effector) T cells were 0.4%, 74.4%, and 
24.8% of MRP3765 CD8
+ tetramer+ T cells, respectively. In contrast, phenotypic analysis 
of total CD8+ T cells after vaccination showed that the frequencies of CD45RA-/CCR7+ 
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(central memory), CD45RA-/CCR7- (effector memory), and CD45RA+/CCR7- (effector) 
T cells were 10.7%, 39.4%, and 38.6%, respectively. 
 
Figure 2. Frequencies of Tregs and MDSCs in peripheral blood of HCC patients before 
and after HAIC with MRP3-derived peptide vaccination. (A) Gating strategy of CD4+ 
CD25+ CD127-/low Tregs. Percentages represent the proportions of CD4+ CD25+ 
CD127-/low Tregs among CD4+ cells. The representative results are shown (patient A3). 
(B) Gating strategy of CD14+HLA-DR-/low MDSCs. Percentages represent the 
proportions of CD14+HLA-DR-/low MDSCs among CD14+ cells. The representative 
results are shown (patient B2). (C) The frequency of MRP3-derived peptide-specific T 
cells before treatment was compared with that 2 weeks after final vaccination. The 
frequency of MRP3-derived peptide-specific T cells significantly increased after 
vaccination (p = 0.007). (D) The frequency of Tregs before treatment was compared with 
that 2 weeks after final vaccination. The frequency of Tregs decreased significantly after 
vaccination (p = 0.040). (E) The frequency of MDSCs increased significantly after 
vaccination (p = 0.022). 
 
Figure 3. (A) The kinetics of MRP3765 (peptide 1)-, HIVenv584 (peptide 2)-, and 
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CMVpp65328 (peptide 3)-specific T cell responses, as determined by IFN-γ ELISPOT 
assay in vaccinated patients. PBMCs were obtained at three different time points: before 
and 4 and 24 weeks after vaccination. Each graph indicates the kinetics of 
peptide-specific T cells in each patient. *1, *2, *3 *4, *5, *6 and *7 denote 231, 237, 232, 
255, 99, 139 and 74 specific spots, respectively. (B) Progression-free survival (PFS) 
versus overall survival (OS) from the starting date of HAIC with peptide vaccination in 
HCC patients. 
 
Figure 4. Representative clinical course of the patient with PR. (A) Time course of serum 
ALT, AFP, and DCP in the patient with PR (Patient B3). (B) Dynamic computed 
tomography imaging of a representative radiological response to MRP3-derived peptide 
in the patient with PR (Patient B3). Red arrows show the HCC lesion. (C) Immune 
responses to MRP3-derived peptide (Peptide 1, MRP3765) or control peptides (Peptide 2, 
HIVenv584 and Peptide 3, CMVpp65328) in the HCC patient with PR (Patient B3). 
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Table 1  Patient characteristics 
Patient Peptide  
Dose  
(mg) 


























A1 0.03 68 M HCV IVb 144 350 LC B 51 10 - + mod 
A2 0.03 66 M HCV III 35 9 LC B 33 11 - - ND 
A3 0.03 63 M HCV II 72 89 CH B 16 12 - - well 
B1 0.3 74 M HCV II 50 12 LC B 20 16 - - ND 
B2 0.3 73 M NBNC IVa 54 4023 LC A 52 5 + - ND 
B3 0.3 58 F NBNC III 28 181 CH A 97 1 + - por 
C1 3.0 72 M HCV II 22 86 LC B 19 8 - - ND 
C2 3.0 64 M NBNC IVa 24 284 LC A 27 10 + - ND 
C3 3.0 66 M HCV IVa 54 14890 LC B 42 6 + - mod 
C4 3.0 58 F NBNC III 31 20 LC B 60 6 - - mod 
C5 3.0 73 M HCV II 42 617 LC B 16 6 - - ND 
C6 3.0 71 M NBNC IVa 55 26 LC A 77 10 + - por 
  HCV, hepatitis C virus; NBNC, not hepatitis B and C virus; LC, liver cirrhosis; CH, chronic hepatitis; wel, well differentiated; mod, 
moderately differentiated; por, poorly differentiated; ND, not determined. 
1Tumor size was indicated as a diameter of the largest tumor in the liver. 2Histological degree of HCC. 
  
  
Table 2 Summary of toxicity 
Toxicity  Grade  Total patients 
 1 2 3 (n=12)(%) 
Constitutional symptoms     
Fever 3 0 0 3(25.0) 
Dizziness 1 0 0 1(8.3) 
     
Gastrointestinal disorders     
Ascites 0 3 0 3(25.0) 
Gastric ulcer 0 2 0 2(16.7) 
     
Musculoskeletal and connective tissue disorders     
Arthralgia 1 0 0 1(8.3) 
     
Investigations     
Neutrophil count decreased 0 1 0 1(8.3) 






Table 3 Summary of immune and tumor responses after vaccination with the MRP3-derived peptide 
Patient   ELISPOT  Increase of MDSCs* Best study response Overall survival time 
  Pre After 1 course After 2 course  (CR/PR/SD/PD) (days) 
A1  - - + + SD 272 
A2  - ND - + SD 416 
A3  - - + + SD 514 
B1  - ND - - SD 938 
B2  - - ND + PD 561 
B3  - + + - PR 552 
C1  - ND + - SD 454 
C2  - ND ND ND PD 47 
C3  - + ND - SD 105 
C4  - - + - SD 340 
C5  - - + - SD 586 
C6  - ND + + SD 333 
      A significant increased % of MDSCs after vaccination was defined as more than 10%. 
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